We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
One of the most difficult sectors to invest in is the healthcare sector. Not only do you have to be nuanced in the ways of the stock market but you also have to have a deep understanding of medicines, machines, and biology in general.
Whether you were looking at medical instruments and devices or biotechnology stocks the goal is always the same thing. Investors are looking for what will work today and tomorrow and how to be best positioned for down the road.
One stock that is getting a lot of attention is Hims & Hers (HIMS - Free Report) . This company delivers medicine discreetly to your door but has been running hard ever since it started including GLP1 weight loss drugs. Savvy investors know that there is a shortage of GLP which allows HIMS to be in this space, but it won’t last forever. There is a significant short interest position on the stock, but that hasn’t slowed investors from gobbling up shares.
In the video attached to this article we take a look at HIMS.
Another aspect that must be understood is medical devices. Veracyte (VCYT - Free Report) is a Zacks Rank #1 (Strong Buy) that has Zacks Style Scores that will attract growth investors. The Zacks Style Score for value is an F while the Zacks Style Score for Growth is an A. I like to say that when I see that type of divergence in the style scores I know I am on the right path as an aggressive growth investor.
Veracyte (VCYT - Free Report) is profiled in the video that is related to this article.
Drugs that pass the rigorous testing of Phase I, Phase II and Phase III become commercialized and many go on to post enormous profits. At some time, however, the FDA allows for a generic equivalent to be produced and sold. BridgeBio Pharma (BBIO - Free Report) is a company that does just that. The stock is currently a Zacks Rank #2 (Strong Buy) and with inflation eating away at consumers wallets, the likelihood of switching to a generic (when available) is very strong.
Now all of this is very complex and can be overwhelming for regular investors. To solve this problem Zacks has a service called Healthcare Innovators and is run by Kevin Cook.
Kevin is an accomplished trader and he has embraced the healthcare sector like few others. He has obtained a deep understanding of biotechnology companies as well as medical device manufacturers and even the insurance providers in the space.
When we combine an accomplished trader with a thorough understanding of the healthcare sector we have a very powerful tool. Kevin leverages the Zacks Rank to help him make trades and long term investments in the best healthcare stocks.
Be sure to check out Healthcare Innovators at www.Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Brian's Big Idea: Healthcare Stocks
One of the most difficult sectors to invest in is the healthcare sector. Not only do you have to be nuanced in the ways of the stock market but you also have to have a deep understanding of medicines, machines, and biology in general.
Whether you were looking at medical instruments and devices or biotechnology stocks the goal is always the same thing. Investors are looking for what will work today and tomorrow and how to be best positioned for down the road.
One stock that is getting a lot of attention is Hims & Hers (HIMS - Free Report) . This company delivers medicine discreetly to your door but has been running hard ever since it started including GLP1 weight loss drugs. Savvy investors know that there is a shortage of GLP which allows HIMS to be in this space, but it won’t last forever. There is a significant short interest position on the stock, but that hasn’t slowed investors from gobbling up shares.
In the video attached to this article we take a look at HIMS.
Another aspect that must be understood is medical devices. Veracyte (VCYT - Free Report) is a Zacks Rank #1 (Strong Buy) that has Zacks Style Scores that will attract growth investors. The Zacks Style Score for value is an F while the Zacks Style Score for Growth is an A. I like to say that when I see that type of divergence in the style scores I know I am on the right path as an aggressive growth investor.
Veracyte (VCYT - Free Report) is profiled in the video that is related to this article.
Drugs that pass the rigorous testing of Phase I, Phase II and Phase III become commercialized and many go on to post enormous profits. At some time, however, the FDA allows for a generic equivalent to be produced and sold. BridgeBio Pharma (BBIO - Free Report) is a company that does just that. The stock is currently a Zacks Rank #2 (Strong Buy) and with inflation eating away at consumers wallets, the likelihood of switching to a generic (when available) is very strong.
Now all of this is very complex and can be overwhelming for regular investors. To solve this problem Zacks has a service called Healthcare Innovators and is run by Kevin Cook.
Kevin is an accomplished trader and he has embraced the healthcare sector like few others. He has obtained a deep understanding of biotechnology companies as well as medical device manufacturers and even the insurance providers in the space.
When we combine an accomplished trader with a thorough understanding of the healthcare sector we have a very powerful tool. Kevin leverages the Zacks Rank to help him make trades and long term investments in the best healthcare stocks.
Be sure to check out Healthcare Innovators at www.Zacks.com.